Detalles de la búsqueda
1.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
N Engl J Med
; 390(10): 875-888, 2024 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38446675
2.
Biocompatible surface functionalization architecture for a diamond quantum sensor.
Proc Natl Acad Sci U S A
; 119(8)2022 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35193961
3.
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
N Engl J Med
; 384(12): 1125-1135, 2021 03 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33577729
4.
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 24(11): 1252-1265, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37844597
5.
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Prostate
; 83(4): 376-384, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564933
6.
Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
BMC Cancer
; 23(1): 1056, 2023 Nov 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37919668
7.
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Lancet Oncol
; 23(2): 248-258, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35030333
8.
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
Oncologist
; 27(12): 1048-1057, 2022 12 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36146944
9.
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med
; 381(4): 338-348, 2019 07 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31340094
10.
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
BJU Int
; 130(5): 592-603, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34597472
11.
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study.
Acta Oncol
; 61(1): 52-57, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34736367
12.
Refractory cytokine release reaction to Nivolumab: Following desensitization algorithms to optimize the management of drug hypersensitivity.
J Oncol Pharm Pract
; 28(3): 736-739, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34878360
13.
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
BJU Int
; 128(2): 196-205, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33556233
14.
Modelling of high-temperature order-disorder phase transitions of non-stoichiometric Mo2C and Ti2C from first principles.
Phys Chem Chem Phys
; 23(39): 22305-22312, 2021 Oct 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34590649
15.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 21(12): 1574-1588, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32971005
16.
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Cancer
; 126(6): 1208-1216, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31829450
17.
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
J Urol
; 204(1): 63-70, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31971495
18.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Lancet Oncol
; 20(10): 1370-1385, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31427204
19.
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Lancet
; 391(10122): 748-757, 2018 02 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-29268948
20.
BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
J Transl Med
; 17(1): 386, 2019 11 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31767020